Aktis Oncology to Present Early AKY-2519 Data at ASCO 2026
Event summary
- Aktis Oncology will present first clinical imaging and dosimetry data for AKY-2519 at the 2026 ASCO Annual Meeting.
- AKY-2519, a miniprotein radioconjugate targeting B7-H3, will be featured in two poster presentations.
- Phase 1b clinical trial of AKY-2519 is set to start mid-2026.
- AKY-2519 is the second clinical-stage miniprotein radioconjugate discovered using Aktis’ proprietary platform.
The big picture
Aktis Oncology is advancing its proprietary miniprotein radioconjugate platform, targeting broader patient populations with solid tumors. The presentation of early AKY-2519 data at ASCO 2026 underscores the company's strategic focus on expanding the potential of targeted radiopharmaceuticals beyond existing platform technologies. The Phase 1b trial initiation mid-2026 will be a key milestone in assessing the clinical viability of AKY-2519.
What we're watching
- Clinical Progress
- How the initial imaging and dosimetry data for AKY-2519 will influence investor confidence and regulatory path forward.
- Pipeline Expansion
- Whether Aktis can sustain momentum with both AKY-2519 and AKY-1189 in parallel clinical development.
- Market Positioning
- The pace at which Aktis can differentiate itself in the competitive radiopharmaceutical space.
Related topics